IMMUNIC, INC. quarterly report, Q2 FY2018

Business context and reporting period

This is Vital Therapies, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018, filed August 7, 2018. The supplied company metadata says IMMUNIC, Inc., but the filing identifies the registrant as Vital Therapies, Inc.; verify the intended issuer before relying on this summary.

The clinical-stage biotechnology company had no product revenue and was focused on ELAD, an investigational cell-based liver-support system. Enrollment of 151 subjects in its Phase 3 VTL-308 trial for severe alcoholic hepatitis was completed in March 2018.

Financial results and position

At June 30, 2018, cash and cash equivalents were $31.116 million, down from $56.901 million at December 31, 2017. Total current assets were $32.645 million and current liabilities were $8.299 million. Total liabilities were $8.348 million; the filing shows no debt balance. Stockholders’ equity was $26.453 million and accumulated deficit was $323.023 million. With no product revenue, operating margins are not meaningful.

Material changes versus comparable periods

• Second-quarter R&D expense fell 12% year over year, mainly as VTL-308 enrollment ended; G&A rose 57%, largely due to higher compensation, legal, investor-relations and consulting costs. Total operating expenses rose 3%, and quarterly net loss increased from $12.407 million to $12.682 million.
• For the first six months, R&D expense declined 3%, while G&A increased 49%; total operating expenses rose 9% and net loss increased from $25.009 million to $27.070 million.
• Operating cash use increased to $25.429 million from $21.060 million in the first half of 2017. First-half 2017 financing included $37.679 million net proceeds from common-stock issuance; no comparable offering proceeds were received in 2018.

Outlook, risks and unusual items

• Management expected VTL-308 topline results in the third quarter of 2018, likely in the second half of September. A successful result could support a BLA application, but the filing cautions that one successful trial might not suffice for regulatory approval.
• Assuming limited BLA activity and no substantial commercial build-out, management expected June 30 cash to fund operations through the first quarter of 2019. The company stated it would need additional liquidity thereafter and disclosed substantial doubt about its ability to continue as a going concern for one year from issuance of the financial statements.
• Management planned to seek additional capital if trial results were positive, potentially through equity or debt, partnerships, licensing or other arrangements. The effective shelf registration allowed up to $200 million of company securities, including up to $60 million under an at-the-market facility; no shares had been sold under it by June 30. Financing could dilute shareholders, and funding might not be available on acceptable terms.
• If VTL-308 required more development or failed, management said it might substantially restructure operations, sell assets or potentially liquidate the company. The prior Phase 3 VTI-208 trial failed its primary and secondary endpoints, increasing the importance and risk of VTL-308.
• Other key risks include regulatory approval, clinical-trial interpretation and safety, manufacturing scale-up and reliance on single-source suppliers, reimbursement and commercialization capability. No material litigation was reported. Management said disclosure controls were effective and reported no material change in internal control over financial reporting during the period.

Investor facts to verify

• Confirm the issuer identity: the supplied metadata names IMMUNIC, Inc., while this filing names Vital Therapies, Inc.
• Verify the actual VTL-308 topline outcome and subsequent regulatory or corporate developments; the stated September 2018 timing was forward-looking as of this filing.
• Check subsequent financing, cash runway and going-concern disclosures, including any use of the shelf or at-the-market facility.
• Assess whether the trial data supported a BLA and whether regulators required additional clinical studies.
• Review potential dilution from the 8.499 million outstanding options and the company’s substantial future capital needs.